Cost-Effectiveness of Pembrolizumab Plus Chemotherapy Versus Pembrolizumab Monotherapy in Metastatic Non-Squamous and Squamous NSCLC Patients With PD-L1 Expression ≥ 50%

• Asıl Yazarlar: Qiao Liu (Yazar), Zhen Zhou (Yazar), Xia Luo (Yazar), Lidan Yi (Yazar), Liubao Peng (Yazar), Xiaomin Wan (Yazar), Chongqing Tan (Yazar), Xiaohui Zeng (Yazar)
• Materyal Türü: Kitap
• Baskı/Yayın Bilgisi: Frontiers Media S.A., 2022-01-01T00:00:00Z.
• Konular: article
• Online Erişim: Connect to this object online.

Objective To compare the cost-effectiveness of the combination of pembrolizumab and chemotherapy (Pembro+Chemo) versus pembrolizumab monotherapy (Pembro) as the first-line treatment for metastatic non-squamous and squamous non-small-cell lung cancer (NSCLC) with PD-L1expression ≥50%, respectively, f...